OKAY
833230
CHANGFU CO.,LTD
871396
Gansu Longshenrongfa Pharmaceutical Industry
300534
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
CN Stock MarketDetailed Quotes
002760 Fengxing Co.,Ltd.
- 18.52
- -0.21-1.12%
Not Open Apr 1 15:00 CST
2.00BMarket Cap-32.90P/E (TTM)
18.84High18.47Low36.18KlotVolume18.61Open18.73Pre Close67.53MTurnover3.35%Turnover RatioLossP/E (Static)107.99MShares29.2552wk High2.47P/B2.00BFloat Cap11.4152wk Low20.60Limit Up107.99MShs Float57.70Historical High16.86Limit Down1.98%Amplitude10.39Historical Low0.10Dividend TTM18.67Avg Price18.55KlotAsk0.54%Div YieldTTM100Lot Size17.13KlotBid
Fengxing Co.,Ltd. Key Stats
All
YOY
| (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -14.87%588.08M | -16.06%436.45M | -18.75%301.15M | -15.17%140.34M | -15.36%690.8M | -8.77%519.94M | -4.90%370.66M | -14.95%165.42M | -13.64%816.12M | -14.34%569.94M |
| Operating revenue | -14.87%588.08M | -16.06%436.45M | -18.75%301.15M | -15.17%140.34M | -15.36%690.8M | -8.77%519.94M | -4.90%370.66M | -14.95%165.42M | -13.64%816.12M | -14.34%569.94M |
| Other operating revenue | 37.22%14M | ---- | 50.87%7.43M | ---- | -34.28%10.2M | ---- | -5.20%4.92M | ---- | 39.45%15.52M | ---- |
| Total operating cost | -11.13%626.87M | -12.85%447.08M | -15.67%305.61M | -9.24%144.44M | -9.58%705.34M | -6.29%512.99M | -3.35%362.37M | -13.04%159.14M | -9.15%780.04M | -8.68%547.39M |
| Operating cost | -9.95%503.15M | -13.47%358.72M | -17.20%243.8M | -12.81%112.81M | -13.81%558.72M | -8.59%414.54M | -5.19%294.44M | -15.11%129.39M | -11.12%648.26M | -11.69%453.51M |
| Operating tax surcharges | -10.64%7.04M | -17.19%5.17M | -17.78%3.47M | -13.78%1.63M | 9.18%7.88M | 20.25%6.24M | 23.04%4.22M | -9.74%1.89M | -6.14%7.22M | -11.80%5.19M |
| Operating expense | -11.70%33.75M | -1.90%26.28M | -12.36%17.3M | -5.28%8.24M | 9.16%38.22M | 7.00%26.79M | 10.66%19.74M | -7.74%8.7M | 7.23%35.01M | 9.28%25.04M |
| Administration expense | -5.57%58.19M | 2.77%40.76M | 1.58%25.6M | 21.09%12.57M | 23.99%61.62M | 8.19%39.66M | 2.67%25.2M | -6.07%10.38M | 10.60%49.7M | 16.71%36.66M |
| Financial expense | -104.48%-265.53K | -135.60%-1.75M | -38.50%2.19M | -37.49%1.16M | -20.03%5.93M | 0.70%4.93M | 15.98%3.55M | 130.90%1.86M | 12.97%7.42M | -1.72%4.89M |
| -Interest expense (Financial expense) | -38.05%6.05M | -32.11%5.38M | -40.03%3.33M | -22.21%1.92M | -7.66%9.77M | 6.07%7.92M | 13.11%5.55M | 45.65%2.47M | 22.57%10.58M | 3.75%7.46M |
| -Interest Income (Financial expense) | -63.37%-6.3M | -2,072.26%-6.89M | 41.39%-960.85K | 9.82%-742.18K | -22.79%-3.85M | 87.58%-317.05K | 9.81%-1.64M | 7.76%-822.99K | -11.33%-3.14M | -25.35%-2.55M |
| Research and development | -24.17%25M | -14.00%17.9M | -12.94%13.25M | 16.00%8.03M | 1.66%32.98M | -5.80%20.82M | -1.66%15.22M | -3.80%6.92M | -13.34%32.44M | 6.60%22.1M |
| Credit Impairment Loss | 99.26%-49.6K | 118.99%2.88M | 10.60%2.94M | -79.67%472.75K | -538.73%-6.66M | 1,253.78%1.31M | 37.57%2.66M | 167.07%2.33M | -188.12%-1.04M | -106.12%-113.97K |
| Asset Impairment Loss | 26.27%-54.84M | 97.13%-1.42M | -252.55%-1.02M | -6,726.51%-1.62M | -13,162.21%-74.38M | -83,236.22%-49.48M | 1,166.78%666.53K | -13,658.99%-23.68K | -183.70%-560.88K | 152.50%59.51K |
| Other net revenue | 65.26%-19.65M | 205.54%24.92M | 28.38%17.6M | -22.75%6.02M | -274.74%-56.58M | -192.62%-23.61M | -17.02%13.71M | 9.70%7.8M | 20.41%32.38M | 32.28%25.49M |
| Fair value change income | ---- | --682.81K | --445.7K | ---- | --819.2K | ---- | ---- | ---- | ---- | ---- |
| Invest income | 2,742.56%5.37M | 103.64%1.45M | 100.54%1.05M | 75.52%418.22K | -77.90%189.06K | 258.01%714.48K | 143.06%525.93K | 139.15%238.28K | -22.31%855.57K | -50.18%-452.17K |
| -Including: Investment income associates | ---- | 54.39%1.1M | 33.64%702.83K | 48.73%354.38K | ---- | 258.01%714.48K | 143.06%525.93K | 139.15%238.28K | --855.57K | -50.18%-452.17K |
| Asset deal income | 232.40%46.16K | -206.05%-11.39K | ---19.7K | ---12.69K | -94.27%13.89K | -98.79%10.74K | ---- | ---- | 33.34%242.49K | 24,225.19%888.43K |
| Other revenue | 27.16%29.82M | -10.48%21.33M | 44.00%14.2M | 28.62%6.76M | -28.69%23.45M | -5.11%23.83M | -33.60%9.86M | -23.21%5.26M | 33.56%32.88M | 40.91%25.11M |
| Operating profit | 17.83%-58.44M | 185.76%14.28M | -40.25%13.14M | -86.39%1.92M | -203.89%-71.12M | -134.66%-16.65M | -29.91%22M | -24.29%14.08M | -39.58%68.45M | -43.59%48.04M |
| Add:Non operating Income | -96.93%272.12K | 1,049.29%19.88K | --17.59K | -9.97%6.44K | 47,018.41%8.87M | -95.08%1.73K | ---- | 29.72%7.16K | -98.40%18.82K | 28.40%35.19K |
| Less:Non operating expense | -88.06%106.54K | -83.36%96.14K | -84.67%82.45K | 683.91%5.1K | -46.77%892.55K | 817.30%577.74K | 4,062.57%537.96K | 261.11%650 | 345.93%1.68M | -22.79%62.98K |
| Total profit | 7.71%-58.27M | 182.45%14.21M | -39.06%13.08M | -86.39%1.92M | -194.53%-63.14M | -135.88%-17.23M | -31.63%21.46M | -24.28%14.08M | -41.46%66.8M | -43.58%48.01M |
| Less:Income tax cost | 172.93%2.56M | -114.61%-77.97K | -91.63%34.26K | -296.58%-1.06M | -180.81%-3.5M | -79.89%533.57K | -87.63%409.37K | 689.73%538.99K | -62.07%4.34M | -75.20%2.65M |
| Net profit | -2.00%-60.83M | 180.41%14.28M | -38.04%13.04M | -78.03%2.98M | -195.48%-59.64M | -139.16%-17.76M | -25.03%21.05M | -27.53%13.55M | -39.17%62.46M | -39.04%45.36M |
| Net profit from continuing operation | -2.00%-60.83M | 180.41%14.28M | -38.04%13.04M | -78.03%2.98M | -195.48%-59.64M | -139.16%-17.76M | -25.03%21.05M | -27.53%13.55M | -39.17%62.46M | -39.04%45.36M |
| Net profit of parent company owners | -2.00%-60.83M | 180.41%14.28M | -38.04%13.04M | -78.03%2.98M | -195.48%-59.64M | -139.16%-17.76M | -25.03%21.05M | -27.53%13.55M | -34.58%62.46M | -32.50%45.36M |
| Earning per share | ||||||||||
| Basic earning per share | -3.64%-0.57 | 181.25%0.13 | -36.84%0.12 | -76.92%0.03 | -194.83%-0.55 | -138.10%-0.16 | -26.92%0.19 | -23.53%0.13 | -43.69%0.58 | -44.74%0.42 |
| Diluted earning per share | -3.64%-0.57 | 181.25%0.13 | -36.84%0.12 | -76.92%0.03 | -194.83%-0.55 | -138.10%-0.16 | -26.92%0.19 | -23.53%0.13 | -43.69%0.58 | -44.74%0.42 |
| Other composite income | ||||||||||
| Total composite income | -2.00%-60.83M | 180.41%14.28M | -38.04%13.04M | -78.03%2.98M | -195.48%-59.64M | -139.16%-17.76M | -25.03%21.05M | -27.53%13.55M | -39.17%62.46M | -39.04%45.36M |
| Total composite income of parent company owners | -2.00%-60.83M | 180.41%14.28M | -38.04%13.04M | -78.03%2.98M | -195.48%-59.64M | -139.16%-17.76M | -25.03%21.05M | -27.53%13.55M | -34.58%62.46M | -32.50%45.36M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- |
| Auditor | Rong Cheng Certified Public Accountants (Special General Partnership) | -- | -- | -- | Daxin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Daxin Certified Public Accountants (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.